Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension

Advances in Therapy

Volumn 26, Issue 9, 2009, Pages 813-825

  Montani, David ^a,b   Chaumais, Marie Camille ^a,b   Savale, Laurent ^a,b   Natali, Delphine ^a,b   Price, Laura C ^b,c   Jaïs, Xavier ^a,b   Humbert, Marc ^a,b   Simonneau, Gérald ^a,b   Sitbon, Olivier ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Phosphodiesterase type 5 inhibitors; Pulmonary arterial hypertension; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

BOSENTAN; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; NITRATE; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; SILDENAFIL; TADALAFIL; VARDENAFIL;

BLURRED VISION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; EISENMENGER COMPLEX; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; EXERCISE TOLERANCE; FLUSHING; GASTROINTESTINAL DISEASE; HEALTH STATUS; HEMODYNAMICS; HUMAN; MONOTHERAPY; MYALGIA; NAUSEA; NONHUMAN; NOSE CONGESTION; PATHOGENESIS; PREGNANCY; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE;

ALGORITHMS; CARBOLINES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; HUMANS; HYPERTENSION, PULMONARY; IMIDAZOLES; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PULMONARY VENO-OCCLUSIVE DISEASE; PURINES; SULFONES; TRIAZINES;

EID: 76749132472     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0064-z     Document Type: Review

References (55)

1. G. Simonneau I.M. Robbins M. Beghetti 2009 Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 54 S43 S54 10.1016/j.jacc.2009.04.012 19555858
2. G.E. D'Alonzo R.J. Barst S.M. Ayres 1991 Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann Intern Med 115 343 349 1863023
3. P.M. Hassoun L. Mouthon J.A. Barbera 2009 Inflammation, growth factors, and pulmonary vascular remodeling J Am Coll Cardiol 54 S10 S19 10.1016/j.jacc.2009.04.006 19555853
4. N.W. Morrell S. Adnot S.L. Archer 2009 Cellular and molecular basis of pulmonary arterial hypertension J Am Coll Cardiol 54 S20 S31 10.1016/j.jacc.2009.04.018 19555855
5. J. Wharton J.W. Strange G.M. Moller 2005 Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells Am J Respir Crit Care Med 172 105 113 10.1164/rccm.200411-1587OC 15817798 (Pubitemid 40923321)
6. J.D. Corbin A. Beasley M.A. Blount S.H. Francis 2005 High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors Biochem Biophys Res Commun 334 930 938 10.1016/j.bbrc.2005.06.183 1:CAS:528: DC%2BD2MXmvFSju7o%3D 16023993 (Pubitemid 41033209)
7. S. Moncada A. Higgs 1993 The L-arginine-nitric oxide pathway N Engl J Med 329 2002 2012 10.1056/NEJM199312303292706 1:CAS:528:DyaK2cXhsF2ntrw%3D 7504210 (Pubitemid 24015045)
8. E. Michelakis W. Tymchak D. Lien L. Webster K. Hashimoto S. Archer 2002 Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide Circulation 105 2398 2403 10.1161/01.CIR.0000016641.12984.DC 1:CAS:528:DC%2BD38XkslSmtb4%3D 12021227 (Pubitemid 34556392)
9. B. Tantini A. Manes E. Fiumana 2005 Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells Basic Res Cardiol 100 131 138 10.1007/s00395-004-0504-5 1:CAS:528:DC%2BD2MXjtVGkur8%3D 15739122 (Pubitemid 40361605)
10. K.F. Rabe H. Tenor G. Dent C. Schudt M. Nakashima H. Magnussen 1994 Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors Am J Physiol 266 L536 L543 1:CAS:528:DyaK2cXksFCnsLo%3D 7515580
11. D. Giordano M.E. De Stefano G. Citro A. Modica M. Giorgi 2001 Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain Biochim Biophys Acta 16 1527 1539
12. K.A. Hanson J.W. Ziegler S.D. Rybalkin J.W. Miller S.H. Abman W.R. Clarke 1998 Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity Am J Physiol 275 L931 L941 1:STN:280:DyaK1M%2Fjt1Kksw%3D%3D 9815111
13. A. Giaid M. Yanagisawa D. Langleben 1993 Expression of endothelin-1 in the lungs of patients with pulmonary hypertension N Engl J Med 328 1732 1739 10.1056/NEJM199306173282402 1:STN:280:DyaK3s3mvVensA%3D%3D 8497283 (Pubitemid 23170122)
14. D. Montani R. Souza C. Binkert 2007 Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension Chest 131 101 108 10.1378/chest.06-0682 1:CAS:528:DC%2BD2sXhs1alu7c%3D 17218562 (Pubitemid 46122980)
15. R.J. Barst J.S. Gibbs H.A. Ghofrani 2009 Updated evidence-based treatment algorithm in pulmonary arterial hypertension J Am Coll Cardiol 54 S78 S84 10.1016/j.jacc.2009.04.017 19555861
16. A. Giaid 1998 Nitric oxide and endothelin-1 in pulmonary hypertension Chest 114 208S 212S 10.1378/chest.114.3-Supplement.208S 1:CAS:528: DyaK1cXmtlyjtLc%3D 9741571
17. A. Giaid D. Saleh 1995 Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension N Engl J Med 333 214 221 10.1056/NEJM199507273330403 1:STN:280:DyaK2Mzht1Sgtg%3D%3D 7540722
18. S.L. Archer K. Djaballah M. Humbert 1998 Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension Am J Respir Crit Care Med 158 1061 1067 1:STN:280:DyaK1cvktlaqtA%3D%3D 9769261
19. H.A. Ghofrani I.H. Osterloh F. Grimminger 2006 Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond Nat Rev Drug Discov 5 689 702 10.1038/nrd2030 1:CAS:528:DC%2BD28XnsFCkuro%3D 16883306 (Pubitemid 44151606)
20. V.K. Gopal S.H. Francis J.D. Corbin 2001 Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum Eur J Biochem 268 3304 3312 10.1046/j.1432-1327.2001.02233.x 1:CAS:528:DC%2BD3MXktlSgsbc%3D 11389733 (Pubitemid 32823005)
21. R.T. Schermuly K.P. Kreisselmeier H.A. Ghofrani 2004 Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats Am J Respir Crit Care Med 169 39 45 10.1164/rccm.200302-282OC 12958054
22. H.A. Ghofrani R. Voswinckel F. Reichenberger 2004 Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study J Am Coll Cardiol 44 1488 1496 1:CAS:528:DC%2BD2cXot1WqtL0%3D 15464333
23. P.J. Wright 2006 Comparison of phosphodiesterase type 5 (PDE5) inhibitors Int J Clin Pract 60 967 975 10.1111/j.1742-1241.2006.01049.x 1:CAS:528:DC%2BD28XpvVemsb0%3D 16780568 (Pubitemid 44082288)
24. G. Burgess H. Hoogkamer L. Collings J. Dingemanse 2008 Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil Eur J Clin Pharmacol 64 43 50 10.1007/s00228-007-0408-z 1:CAS:528: DC%2BD1cXjsFyitg%3D%3D 18040672
25. R.E. Wrishko J. Dingemanse A. Yu C. Darstein D.L. Phillips M.I. Mitchell 2008 Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects J Clin Pharmacol 48 610 618 10.1177/0091270008315315 1:CAS:528:DC%2BD1cXlvVGqsbg%3D 18305126
26. M. Humbert E.S. Segal D.G. Kiely J. Carlsen B. Schwierin M.M. Hoeper 2007 Results of European postmarketing surveillance of bosentan in pulmonary hypertension Eur Respir J 30 338 344 10.1183/09031936.00138706 1:CAS:528:DC%2BD2sXpvFCgs7k%3D 17504794 (Pubitemid 47194187)
27. N. Galie H.A. Ghofrani A. Torbicki 2005 Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2148 2157 10.1056/NEJMoa050010 1:CAS:528:DC%2BD2MXht1ajtb%2FI 16291984 (Pubitemid 41653106)
28. G. Simonneau L.J. Rubin N. Galie 2008 Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial Ann Intern Med 149 521 530 18936500
29. N. Galie B.H. Brundage H.A. Ghofrani 2009 Tadalafil therapy for pulmonary arterial hypertension Circulation 119 2894 2903 10.1161/CIRCULATIONAHA.108. 839274 1:CAS:528:DC%2BD1MXms1alsb0%3D 19470885
30. Z.C. Jing X. Jiang B.X. Wu 2009 Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study Heart 95 1531 1536 10.1136/hrt.2009.169417 19549620
31. A.C. Guimaraes M.V. Malachias O.R. Coelho E.C. Zilli R.L. Luna 1999 Use of sildenafil in patients with cardiovascular disease Arq Bras Cardiol 73 515 526 1:STN:280:DC%2BD3cvgtVelsA%3D%3D 10904272
32. R.T. Schermuly S.S. Pullamsetti G. Kwapiszewska 2007 Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy Circulation 115 2331 2339 10.1161/CIRCULATIONAHA.106.676809 1:CAS:528:DC%2BD2sXksFSjtrc%3D 17438150 (Pubitemid 46685901)
33. M. Humbert O. Sitbon G. Simonneau 2004 Treatment of pulmonary arterial hypertension N Engl J Med 351 1425 1436 10.1056/NEJMra040291 1:CAS:528:DC%2BD2cXotVOrs7g%3D 15459304 (Pubitemid 39302645)
34. E. Bedard K. Dimopoulos M.A. Gatzoulis 2009 Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension Eur Heart J 30 256 265 10.1093/eurheartj/ehn597 19147605
35. L.C. Price P. Forrest V. Sodhi 2007 Use of vasopressin after Caesarean section in idiopathic pulmonary arterial hypertension Br J Anaesth 99 552 555 10.1093/bja/aem180 1:CAS:528:DC%2BD2sXhtVWqtrfE 17660458 (Pubitemid 47412500)
36. H.J. Lacassie A.M. Germain G. Valdes M.S. Fernandez F. Allamand H. Lopez 2004 Management of Eisenmenger syndrome in pregnancy with sildenafil and L-arginine Obstet Gynecol 103 1118 1120 15121629
37. V. Molelekwa P. Akhter P. McKenna M. Bowen K. Walsh 2005 Eisenmenger's syndrome in a 27 week pregnancy - management with bosentan and sildenafil Ir Med J 98 87 88 1:STN:280:DC%2BD2M3jsVCqsQ%3D%3D 15869069
38. S. Schafer P. Ellinghaus W. Janssen 2009 Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling Cardiovasc Res 82 30 39 10.1093/cvr/cvp002 19131365
39. S. Bhatia R.P. Frantz C.J. Severson L.A. Durst M.D. McGoon 2003 Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy Mayo Clin Proc 78 1207 1213 10.4065/78.10.1207 1:CAS:528:DC%2BD3sXotlSmt7s%3D 14531479
40. E.D. Michelakis W. Tymchak M. Noga 2003 Longterm treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension Circulation 108 2066 2069 10.1161/01.CIR.0000099502.17776.C2 1:CAS:528:DC%2BD3sXot1Cgsbw%3D 14568893 (Pubitemid 37337580)
41. H.A. Ghofrani R.T. Schermuly F. Rose 2003 Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension Am J Respir Crit Care Med 167 1139 1141 10.1164/rccm.200210-1157BC 12684251 (Pubitemid 36459662)
42. B.K. Sastry C. Narasimhan N.K. Reddy B.S. Raju 2004 Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study J Am Coll Cardiol 43 1149 1153 10.1016/j.jacc.2003.10.056 1:CAS:528:DC%2BD2cXjvFeis7o%3D 15063421 (Pubitemid 38452588)
43. T.P. Singh M. Rohit A. Grover S. Malhotra R. Vijayvergiya 2006 A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension Am Heart J 151 851 10.1016/j.ahj.2005.09.006 16569546
44. D.B. Badesch N.S. Hill G. Burgess 2007 Sildenafil for pulmonary arterial hypertension associated with connective tissue disease J Rheumatol 34 2417 2422 17985403
45. M.R. Wilkins G.A. Paul J.W. Strange 2005 Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study Am J Respir Crit Care Med 171 1292 1297 10.1164/rccm.200410-1411OC 15750042 (Pubitemid 40740738)
46. M.M. Hoeper C. Faulenbach H. Golpon J. Winkler T. Welte J. Niedermeyer 2004 Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Eur Respir J 24 1007 1010 10.1183/09031936.04.00051104 1:CAS:528:DC%2BD2MXhs1KqsA%3D%3D 15572546 (Pubitemid 39642293)
47. H.A. Ghofrani F. Rose R.T. Schermuly 2003 Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension J Am Coll Cardiol 42 158 164 10.1016/S0735-1097(03)00555-2 1:CAS:528: DC%2BD3sXmtVOisrY%3D 12849677 (Pubitemid 36760778)
48. S. Mukhopadhyay M. Sharma S. Ramakrishnan 2006 Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study Circulation 114 1807 1810 10.1161/CIRCULATIONAHA.105.603001 1:CAS:528:DC%2BD28XhtVyitbrP 17030688 (Pubitemid 44673355)
49. K. Aizawa T. Hanaoka H. Kasai 2006 Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension Hypertens Res 29 123 128 10.1291/hypres.29.123 16755146
50. D. Montani L. Achouh P. Dorfmuller 2008 Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology Medicine (Baltimore) 87 220 233 10.1097/MD.0b013e31818193bb
51. D. Montani L.C. Price P. Dorfmuller 2009 Pulmonary veno-occlusive disease Eur Respir J 33 189 200 10.1183/09031936.00090608 1:STN:280: DC%2BD1M%2FkslWrsA%3D%3D 19118230
52. A.C. Barreto S.M. Franchi C.R. Castro A.A. Lopes 2005 Oneyear follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease Braz J Med Biol Res 38 185 195 10.1590/S0100- 879X2005000200006 1:CAS:528:DC%2BD2MXjtVOmsL0%3D 15785829
53. B.C. Creagh-Brown A.G. Nicholson R. Showkathali J.S. Gibbs L.S. Howard 2008 Pulmonary veno-occlusive disease presenting with recurrent pulmonary oedema and the use of nitric oxide to predict response to sildenafil Thorax 63 933 934 10.1136/thx.2007.088831 1:STN:280:DC%2BD1cnjtVGhtQ%3D%3D 18820120
54. Montani D, Jais X, Price LC, et al. Cautious use of epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J. 2009. DOI: 10.1183/09031936.00017809.
55. Montani D, Jaïs X, Dorfmüller P, Simonneau G, Sitbon O, Humbert M. Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution. Eur Respir J. 2009. DOI: 10.1183/09031936.00102609.